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ABSTRACT
Muscle inactivity due to injury or disease results in muscle atrophy. The molecular mechanisms contributing to muscle atrophy are poorly
understood. However, it is clear that expression of atrophy-related genes, like Atrogin-1 and MuRF-1, are intimately tied to loss of muscle
mass. When these atrophy-related genes are knocked out, inactive muscles retain mass. Muscle denervation stimulates muscle atrophy and
Myogenin (Myog) is a muscle-specific transcription factor that is highly induced following muscle denervation. To investigate if Myog
contributes to muscle atrophy, we have taken advantage of conditional Myog null mice. We show that in the denervated soleus muscle Myog
expression contributes to reduced muscle force, mass, and cross-sectional area. We found that Myog mediates these effects, at least in part, by
regulating expression of the Atrogin-1 and MuRF-1 genes. Indeed Myog over-expression in innervated muscle stimulates Atrogin-1 gene
expression andMyog over-expression stimulatesAtrogin-1 promoter activity. Thus, Myog and the signaling cascades regulating its induction
following muscle denervation may represent novel targets for therapies aimed at reducing denervation-induced muscle atrophy. J. Cell.
Biochem. 112: 2149–2159, 2011.  2011 Wiley-Liss, Inc.
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D isease and injury of the neuromuscular system often resultsin lost muscle activity which leads to muscle atrophy. This
atrophy is a consequence of catabolism of muscle proteins.
Although muscle catabolism can be beneficial in times of need,
its long term consequences can be dire. Interestingly, not all muscles
atrophy to the same extent in response to inactivity. Muscles
enriched with slow fiber types, such as the soleus muscle, atrophy to
a greater extent than those with predominantly fast fiber-types
[Grossman et al., 1998]. During soleus muscle atrophy, slow fiber-
type myosin heavy chain isoforms are lost, while faster type II
isoforms are increased [Grossman et al., 1998].
One approach for identifying ways of preventing or reversing the
detrimental consequences of muscle atrophy is to identify
mechanisms underlying this process. It is hoped that these
mechanisms may suggest novel strategies for intervention. In
general, muscle atrophy is accompanied by activation of the
ubiquitin-proteosome system [Cao et al., 2005; Ventadour and
Attaix, 2006]. In this system proteins are targeted for degradation by
being polyubiquinated and then degraded by the 26S proteosome.
Two ubiquitin-protein ligases, Atrogin-1 (Fbxo32/MAFbx) and
MuRF-1 (Trim63), are induced in atrophying skeletal muscle and
knockout mice lacking either of these ligases exhibit reduced
denervation-dependent muscle atrophy [Bodine et al., 2001a;
Gomes et al., 2001]. Although muscle atrophy is most dramatic
around 2–4 weeks following muscle denervation, the expression of
Atrogin-1 and MuRF-1 transcripts peak around 3 days post-
denervation when the rate of muscle weight loss is most rapid
[Sacheck et al., 2007].
A number of studies have shown that activation of the IGF-1/
PI3K/AKT signaling pathway can stimulate muscle hypertrophy and
inhibition of this pathway can lead to muscle atrophy [Bodine et al.,
2001b; Rommel et al., 2001; Stitt et al., 2004]. This pathway was also
shown to regulate Atrogin-1 expression via phosphorylation of
FoxO transcription factors [Sandri et al., 2004; Sandri et al., 2006].
In addition, denervation-dependent suppression of PGC-1a (per-
oxisome proliferator-activated receptor g-coactivator 1a) expres-
sion stimulates muscle atrophy by relieving repression of Atrogin-1
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weak inducer of apoptosis (TWEAK), can stimulate muscle atrophy
via a NF-kB signaling pathway that regulates MuRF-1 expression
[Mittal et al., 2010].
We reasoned that muscle-specific transcription factors that are
also regulated in an activity-dependent manner may be good
candidates for regulating genes, like Atrogin-1 and MuRF-1, which
stimulate muscle atrophy. One such gene encodes Myogenin (Myog),
a basic helix-loop-helix transcription factor that is necessary for
muscle differentiation and is regulated by muscle activity [Eftimie
et al., 1991; Hasty et al., 1993]. Indeed, while this article was in
preparation, it was reported that Myog contributes to denervation-
dependent muscle atrophy by controlling expression of atrophy-
related genes like MuRF-1 and Atrogin-1 [Moresi et al., 2010].
However, these studies were confined to relatively fast muscles and
did not investigate if Myog also regulates atrophy of slow muscles.
Furthermore, these previous studies did not investigate if any of the
consequences of muscle denervation and Myog deletion were a
result of compensation by the contralateral innervated muscle or
due to increase satellite cell proliferation and fusion.
Here, we report that Myog contributes to denervation-dependent
atrophy of the slow soleus muscle via regulated expression of
Atrogin-1 and MuRF-1 gene expression. We demonstrate that this
effect is intrinsic to the denervated hindlimb and not a result of
compensation by the contralateral limb or by increased myoblast
proliferation and fusion in the Myog null denervated muscle. Our
data suggest that denervation-induced muscle atrophy, and its
regulation by Myog, is more dramatic in the predominantly slow
soleus muscle compared to the fast extensor digitorum longus (EDL)
muscle. We go on to show that attenuation of muscle atrophy by
Myog is also reflected in muscle function (force generation). Finally,
consistent with the idea that Myog directly regulates Atrogin-1 and
MuRF-1 gene expression, we show that all three genes are
coordinately suppressed by muscle electrical activity and that
distal E-boxes in the Atrogin-1 promoter are most effective in
mediating Myog-dependent promoter regulation. These data, along
with those of Moresi et al., 2010, suggest Myog induction in
denervated muscle contributes to the development of muscle
atrophy via regulated expression of ubiquitin ligases Atrogin-1 and
Murf-1.
MATERIALS AND METHODS
ANIMALS AND TAMOXIFEN-INDUCED RECOMBINATION
All animal studies were approved by the University of Michigan
Committee on Use and Care of Animals. Myog conditional knockout
mice (Myogflox/flox;CAGG-CreERTM) were described previously
[Knapp et al., 2006]. To induce recombination in Myog conditional
knockout mice, 1mg of tamoxifen suspended in sunflower seed oil
was injected intraperitoneally into adult mice for five consecutive
days followed by a 2 day rest and then repeated. Tamoxifen-induced
recombination should result in deletion of exon 1 in the Myog gene
[Knapp et al., 2006]. Myog exon 1 deletion was confirmed by
polymerase chain reaction (PCR) using genomic DNA isolated from
EDL muscles of Wt (wild type) and Myogflox/flox;CAGG-CreERTM
tamoxifen injected mice. EDL muscles were dissected, lysed in
100ml of 25mM NaOH, 0.2mM EDTA at 958C for 20min and then
buffered by addition of an equal volume of 40mM Tris-HCl (pH 7.8).
Samples were vortexed briefly and centrifuged at 2,000 rpm for
10min. One microliter of lysed muscle containing genomic DNA
was used for each PCR reaction. To test for tamoxifen-induce
recombination, primers were designed to amplify a genomic DNA
fragment spanning the majority of exon 1 (forward primer
50CTACCAGGAGCCCCACTTCTATGATG) and a portion of exon 2
(reverse primer 50AGGAGGCGCTGTGGGAGTTGC). Amplification of
genomic g-actin DNA was performed with forward 50AGAAGAA-
ATCGCCGCACTCGTCAT and reverse 50CCTCTTGCTCTGGGCCTC-
GTCAC primers and served as an internal loading control. We also
confirmed the efficacy of tamoxifen-induced recombination in
adult mice by assaying Myog mRNA in mice treated with and
without tamoxifen following denervation of the tibialis anterior
muscle (see below for muscle denervation protocol, satellite cell
protocol, RNA isolation protocol, and primers used to assay Myog
mRNA levels).
MUSCLE DENERVATION
Muscle denervation was used to induce muscle atrophy and
investigate the consequences of muscle denervation on muscle
function and gene expression. For muscle denervation experiments,
mice were anesthetized by intraperitoneal injection of ketamine
(100mg/kg) and xylazine (10mg/kg). Fur covering the lower back to
proximal thigh was removed; the region was swabbed with Betadine
and a small posterolateral cutaneous incision (1–2 cm) was made
beginning near the sciatic notch. The superficial facia was cut and
the hamstring and gluteal muscles were separated bluntly to reveal
the sciatic nerve. A 1 cm long region of the sciatic nerve was excised
and the incision was closed with wound clips. Three to fourteen days
later muscles were harvested for molecular and physiological assays.
SATELLITE CELL PROLIFERATION IN DENERVATED MUSCLE AND
CELL CULTURE
To assay satellite cell proliferation in denervated muscle, bromo-
deoxyuridine (BrdU, 50mg/kg dissolved in 100ml of 0.9% saline)
was intraperitoneally injected daily, beginning at 5 days post-
denervation and continuing for the next 8 days. Dissected soleus
muscles were embedded in OCT, frozen in liquid nitrogen, sectioned
to 10mm and fixed in 4% paraformaldehyde. Immunofluorescence
was performed as previously described [Ramachandran et al., 2010],
using the following primary antibodies: mouse anti-laminin B2, D18
(Developmental Studies Hybridoma Bank, University of Iowa, 1:25
dilution); rat anti-BrdU (Abcam, 1:500 dilution). Secondary
antibodies were conjugated to Alexa Fluor 488 or Cy3 and used
at 1:500 for anti-mouse and 1:250 for anti-rat. For BrdU detection,
sections were pre-treated with 2N HCl for 20min at 378C and then
soaked in 100mM sodium borate for 10min. Following immuno-
histochemical staining, slides were rinsed with water and allowed to
dry in the dark before cover-slipping with 2.5% (w/v) PVA
(polyvinyl alcohol)/DABCO (1,4 diazabicyclo (2.2.2)octane). Slides
were examined in a Zeiss Axiophot fluorescence microscope
equipped with a digital camera.
Muscle satellite cells were purified from EDL and soleus muscles
to determine if tamoxifen-induced recombination successfully
deleted the Myog gene in satellite cells. Muscles were isolated from
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innervated and 3 day denervated Wt and Myogflox/flox;CAGG-
CreERTM mice that were previously treated with tamoxifen as
described above. Dissected muscles were incubated in collagenase
(0.2% w/v) at 378C for 1.5–2 h, washed 3 with DMEM and
triturated through a wide bore glass pipette that was pre-coated with
horse serum and then triturated through a P1000 pipetman blue tip.
Muscle fragments in 2–4ml of DMEM were transferred to a 15ml
Falcon tube and allowed to settle for 10min. After removing the
supernatant, muscle fragments were resuspended in 7ml of 20%
fetal bovine serum, DMEM, and 1 antibiotics and distributed into
tissue culture plates coated with Matrigel. The following day muscle
fragments were removed, satellite cells allowed to proliferate and 3–
4 days later harvested for RNA isolation and RT-PCR.
MUSCLE DENERVATION AND ELECTRICAL STIMULATION
We used direct stimulation of denervated muscle with extracellular
electrodes to examine if Atrogin-1 and MuRF-1 gene expression,
likeMyog gene expression, is regulated by muscle electrical activity.
Denervation and electrical stimulation were carried out on rat soleus
muscle as previously described [Goldman et al., 1988]. Briefly, the
lower hind limb muscles were bilaterally denervated in anesthetized
Sprague Dawley rats by removing a small segment of the sciatic
nerve at mid thigh. Stimulating electrodes were implanted into one
hind limb and the soleus muscle was stimulated chronically for up to
2 days in 100Hz trains, 1 s duration, applied once every 100 s.
Stimulus pulses within trains were of alternating polarity, their
duration was 0.5ms and their strength was 10–15mA. At the end of
the stimulation period, stimulated and contralateral unstimulated
soleus muscles were excised and RNA extracted for RT-PCR.
MUSCLE FORCE, FIBER AREA, AND MASS MEASUREMENTS
To investigate the consequences of muscle denervation and Myog
deletion on muscle atrophy, muscle force, area, and mass were
measured. Innervated and 14 day denervated soleus and EDL
muscles were isolated from adult Wt and tamoxifen treated Myog
conditional knockout mice. Suture ties (5–0) were secured around
the distal and proximal tendons, and the muscles were carefully
removed and placed in a horizontal bath containing buffered
mammalian Ringer solution (137mM NaCl, 24mM NaHCO3, 11mM
glucose, 5mM KCl, 2mM CaCl2, 1mM MgSO4, 1mM NaH2PO4, and
0.025mM turbocurarine chloride) maintained at 258C and bubbled
with 95%O2–5% CO2 to stabilize pH at 7.4. One tendon of themuscle
was tied securely to a force transducer (model BG-50, Kulite
Semiconductor Products, Leonia, NJ) and the other tendon to a fixed
post.
To determinemaximum isometric tetanic force (Po), muscles were
stimulated between two stainless steel plate electrodes. The voltage
of single 0.2-ms square stimulation pulses and, subsequently,
muscle length were adjusted to obtain maximum twitch force. The
muscle length at which maximum twitch force was obtained was
measured with calipers to determine the optimal length for force
development (Lo). With the muscle held at Lo, the force developed
during trains of stimulation pulses was recorded, and stimulation
frequency was increased until the maximum isometric tetanic force
(Po) was achieved. For each muscle, optimum fiber length (Lf) was
calculated by multiplying Lo by previously determined Lf/Lo ratios
for EDL and soleus muscles of 0.45 and 0.71, respectively [Brooks
and Faulkner, 1988]. After force measurements, muscles were
removed from the bath, the tendons were trimmed, and the muscle
was blotted and weighed. Muscles were quick frozen in isopentane
cooled with liquid nitrogen and stored at –808C for subsequent
histological analyses. Total muscle cross-sectional area (CSA) was
calculated by dividing the muscle mass by the product of Lf and the
density of mammalian skeletal muscle, 1.06 g/cm3. Changes in
average muscle fiber CSAs after denervation were determined on
muscle cryo-sections (14mm) taken from the mid-region of soleus
muscles. Muscle sections were stained with hematoxylin and eosin
to identify the borders of individual muscle fibers and the areas of
100 fibers/muscle were determined with ImageJ (NIH). Changes in
muscle mass, Po, total CSA, and average fiber area after denervation
are expressed relative to corresponding contra lateral innervated
muscles (n¼ 4 for each condition except where identified).
Differences between the experimental andWt samples were assessed
by a 2-tailed Student’s t test, with the assumption of 2-sample equal
variance. Values are expressed as means 1 SEM and significance
was set a priori at P< 0.05.
IN VIVO MUSCLE ELECTROPORATION
We used electroporation to facilitate DNA uptake by muscle fibers in
order to investigate the consequences of Myog overexpression on
Atrogin-1 and MuRF-1 gene expression and Atrogin-1 promoter
activity. For in vivoMyog overexpression, 5mg pCS2:EGFP plasmid
(gift from D. Turner, University of Michigan, Ann Arbor) and either
20mg of pCS2:Myog [Tang et al., 2001] or control empty vector
(pCS2) were injected into innervated soleus muscles of anesthetized
adult mice. For in vivo analysis of Atrogin-1 promoter activity,
15mg of pCS2:Myog or pCS2 along with 5mg of pCS2:EGFP, 5mg of
the Atrogin-1:luciferase reporter plasmid [Sandri et al., 2004] and
5mg of the normalization vector, ubC:Renilla luciferase (gift fromM.
Uhler, University of Michigan, Ann Arbor), were injected into left
and right hindlimb innervated EDL or soleus muscles. Plasmid
uptake was facilitated by placing square flat stainless steel
electrodes, coated with ultrasound transmission gel, on each side
of the leg and using a BTX840 square wave electroporator to deliver
eight pulses of 140V/cm of 60-ms duration with an interval of
100ms. Mice were allowed to recover 12 days before isolation of
electroporated GFPþ fibers (for Myog over-expression in innervated
muscle) or before denervation (for Atrogin-1 promoter analysis).
Electroporated GFPþ fibers were identified under a stereomicro-
scope (Leica MZFLIII) equipped with fluorescence optics. GFPþ
fibers were dissected in ice-cold phosphate-buffered saline (PBS)
and then immediately lysed for RNA and luciferase assays. All
experiments were performed in triplicate and results are expressed
as mean SEM. RNA levels were assayed by RT-PCR using the
following primers: g-Actin forward 50CCAGGCATTGCTGACAGGA-
TGC and reverse 50GTCCATCTAGAAGCATTTGCGGTGGACG; Myog
forward 50GAGAAGCACCCTGCTCAAC and reverse 50GGTGACA-
GACATATCCTCC; Atrogin-1 forward 50GTCCAGAGAGTCGGCAA-
GTC and reverse 50GTAGCCGGTCTTCACTGAGC and MuRF-1
forward 50GAGAACCTGGAGAAGCAGCT and reverse 50CCGCGG-
TTGGTCCAGTAG.
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RNA ISOLATION AND REAL-TIME PCR
Total RNA was isolated using TRIzol (Invitrogen). The Turbo DNase
Kit (Ambion) was used to remove residual DNA and total RNA was
quantified spectrophotometrically. One microgram of total RNA was
used to generated cDNA with oligo (dT) primers and Superscript II
reverse transcriptase (Invitrogen). Real-time PCR was performed
with SYBR green mix (1:20,000 SYBR green) on an iCycler iQ real-
time detection system (BioRad) according to the manufacturer’s
instructions. Each reaction was performed in triplicate on at least
three samples for each condition in a volume of 20ml. The specificity
and efficiency of the primers used in real-time PCR were first
verified by 1% agarose gel electrophoresis. PCR cycles were 958C for
5min, 958C for 30 s, 588C for 30 s, and 728C for 30 s (total 40 cycles).
All real-time PCR results were normalized to g-Actin. The primers
used are: Myog forward 50-AGTGAATGCAACTCCCACAG and
reverse 50-CTGGGAAGGCAACAGACATA; Atrogin-1 forward 50-
AACCGGGAGGCCAGCTAAAGAACA and reverse 50-TGGGCCTA-
CAGAACAGACAGTGC;MuRF-1 forward 50-GAGAACCTGGAGAA-
GCAGCT and reverse 50-CCGCGGTTGGTCCAGTAG; FoxO3 forward
50-ATCGCCTCCTGGCGGGCTTA and reverse 50-ACGGCGGTGC-
TAGCCTGAGA; g-actin forward 50-AGAAGAAATCGCCGCACTC-
GTCAT and reverse 50-CCTCTTGCTCTGGGCCTCGTCAC. Results are
expressed as means SEM.
WESTERN BLOTS
Western blots were used to investigate if denervation-dependent
Myog protein induction preceded denervation-dependent induction
of atrophy-related genes. Western blotting was performed as
previously described [Kostrominova et al., 2000]. Briefly, muscles
were dissected, frozen in liquid nitrogen, pulverized and homo-
genized in 20mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 1mM
phenymethylsulfonyl fluoride and 1mM each of leupeptin and
pepstatin A. Protein concentration was determined using the BioRad
detergent compatible protein assay. Protein samples were resolved
by SDS-PAGE (10%) and transferred electrophoretically to PVDF
membranes. Membranes were blocked in Blotto buffer containing
5% dry milk, 0.05% Tween 20 and incubated overnight at 48C with
mouse monoclonal anti-myogenin antibody (1:50 dilution; clone
F5D, Developmental Studies Hybridoma Bank, The University of
Iowa, Iowa City). Secondary antibody was goat anti-mouse HRP
used at 1:200 dilution and BM chemiluminescence detection was
done according to manufacturers protocol (Roche). Blots were
stripped and reprobed with anti-sarcomeric myosin antibody (1:250
dilution; clone MF20, Developmental Studies Hybridoma Bank, The
University of Iowa, Iowa City).
RESULTS
CONDITIONAL MYOG GENE DELETION IN ADULT MICE
We used Myogflox/flox;CAGG-CreERTM [Knapp et al., 2006] to delete
the Myog gene in adult animals. Tamoxifen treatment of adult
Myogflox/flox;CAGG-CreERTM mice should induce recombination of
the floxedMyog gene and preventMyog gene expression. The Myog
gene contains three exons, and exon 1 is flanked by loxP sites in the
Myogflox/flox;CAGG-CreERTM mouse. Using PCR primers designed to
amplify exon 1, we find that our regimen of tamoxifen treatment
results in its deletion (Fig. 1, top panel). Because Myog gene
expression is low in innervated muscle and highly induced
following muscle denervation [Eftimie et al., 1991; Kostrominova
et al., 2000; Tang and Goldman, 2006; Tang et al., 2006; Tang et al.,
2009], one can also test the efficacy of tamoxifen treatment by
assayingMyog RNA levels in innervated and denervated muscle. For
this analysis we injected Myogflox/flox;CAGG-CreERTM mice with
tamoxifen or vehicle and then the left lower hindlimb muscles were
denervated by cutting the sciatic nerve. Seven days later, innervated
(right hindlimb) and denervated (left hindlimb) muscles were
dissected and Myog and g-actin mRNA levels assayed by RT-PCR.
We found that innervated muscles of control and tamoxifen-treated
mice expressed very low to undetectable levels ofMyog mRNA (Fig.
1, bottom panel). In contrast, muscle denervation dramatically
induced Myog expression only in control mice that did not receive
tamoxifen, while Myog expression remained undetectable in
denervated muscles of mice that received tamoxifen (Fig. 1, bottom
panel). We also isolated satellite cells from innervated and
Fig. 1. Conditional ablation of Myog gene expression. Myogflox/flox;CAGG-
CreERTM mice were injected with vehicle (Con) or tamoxifen (Tam) for 5 days.
Left lower hindlimb muscles were denervated by sciatic nerve transection and
3–7 days later innervated and denervated muscles were dissected. Genomic
DNA was isolated for PCR amplification of exon 1 from the Myog gene (top
panel). RNA was isolated from satellite cells (middle panel) or from muscle
(bottom panel). Shown are ethidium bromide stained gels used to resolve the
amplified gene products. Note that tamoxifen treatment prevented amplifica-
tion of genomic DNA containing exon 1 of the Myog gene (top panel) and also
prevented denervation-dependent Myog mRNA induction (Denþ Tam) (middle
and bottom panels), while animals that did not receive tamoxifen showed a
large increase in Myog mRNA expression following muscle denervation (Com-
pare Inn and Den lanes in the middle and bottom panels). Experiments were
done in duplicate.
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denervated muscle to determine if tamoxifen treatment deleted
Myog from satellite cells.Myog expression is undetectable in satellite
cells isolated from innervated muscle and increased in satellite cells
isolated from denervated muscle; however, following tamoxifen
treatment Myog remains undetectable in muscle satellite cells
isolated from denervated muscle (Fig. 1, middle panel).
MYOG CONTRIBUTES TO MUSCLE MASS, FORCE, AND CSAS
We next deleted Myog in adult mice and denervated the left lower
hindlimb muscles for 14 days; a similar denervation protocol was
performed on Wt mice for comparison. During preliminary
experiments we determined that 2 weeks of muscle denervation
had no significant effect on either muscle mass or maximum
isometric force in the contralateral innervated soleus or EDL muscle
of denervated animals when compared to muscles isolated from age
and weight matched mice whose muscles remained innervated
(Fig. 2A and B). Consequently, all subsequent experiments were
performed making use of the contralateral innervated limb as the
internal control. Fast fiber-type EDL and slow fiber-type soleus
muscles were then dissected for measurements of muscle mass,
force, and CSA. Consistent with that reported by others [Grossman
et al., 1998], we found that the slow soleus muscle atrophied to a
greater extent (44% loss in muscle mass) than the fast EDL muscle
(26% loss in muscle mass) (Fig. 2C). Interestingly, soleus and EDL
muscle atrophy was attenuated in Myog knockout mice where they
lost only about half as much mass as the Wt animals (22% loss of
mass for soleus and 14% loss in mass for EDL) (Fig. 2C). Similar to
muscle mass measurements, the maximum isometric force devel-
oped by denervated EDL and soleus muscles was significantly less
than the contralateral innervated muscles (Fig. 2D). However, in this
case there was no significant difference between Wt and Myog
knockout animals in the magnitude of the force decrease in EDL
muscles (20%), while in soleus muscles the decreases in maximum
isometric force were much greater forWt thanMyog knockout mice
(42% vs. 22%, respectively) (Fig. 2D). In general, these data are
consistent with the hypothesis that Myog plays a regulatory role
during the development of muscle atrophy. The lack of a significant
effect ofMyog knockout on the development of maximum isometric
force in EDL muscles is perplexing. We speculate that this is due, in
part, to the relatively small amount of atrophy observed in the EDL
Fig. 2. Myog deletion inhibits denervation-dependent reductions in muscle mass and force. The left lower hindlimb muscles of Wt or Myog null (Myog/) mice were
denervated for 14 days. Innervated and denervated EDL and soleus muscles were then dissected and muscle mass (A) and force (B) assayed. Reported is the denervated mass and
force relative to the contralateral innervated muscle. Note that Myog deletion attenuates denervation-dependent loss in muscle mass and force, especially for the soleus muscle.
Error bars are standard error of the mean (n¼ 4).
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muscles which limited our ability to resolve differences in force.
Because of the much larger differences in both mass and maximum
force development in the denervated soleus muscles ofWt andMyog
knockout mice, we chose to focus our experiments on this muscle.
When mass and force values were used to deduce muscle CSAs,
we also found a statistically significant attenuation of denervation-
induced atrophy in the soleus muscle (Fig. 3A). To more carefully
examine this, we sectioned soleus muscle from innervated and
14 day denervatedWt andMyog knockout mice and quantified fiber
CSAs. Consistent with our force and mass measurements, this
analysis indicated that individual fibers atrophied less in the absence
of Myog (Fig. 3B). Calculations of CSAs from 100 random fibers
indicated a denervation-dependent reduction in fiber CSA of
51.5 3.9% in Wt soleus muscle and only 34 3.4% reduction in
soleus muscle fibers lacking Myog expression.
We next investigated if Myog deletion had a consequence on
satellite cell proliferation and fusion with denervated muscle fibers
which may account for preservation of muscle mass in Myog
knockout animals. For these experiments we treated Wt and Myog
knockout mice with BrdU after muscle denervation. Two weeks later
soleus muscles were monitored for BrdU incorporation into
denervated muscle fibers. Although, we were able to detect scattered
BrdU labeled satellite cells in the interstitial regions of Wt animals
(22 4 BrdUþ cells/soleus muscle, n¼ 3) there was no BrdU-
labeled nuclei in Myog knockout animals (Fig. 3C). Therefore,
increased satellite cell proliferation and fusion cannot explain the
maintenance of muscle mass in Myog knockout animals.
MYOG, ATROGIN-1, AND MURF-1 GENE EXPRESSION ARE
COORDINATELY REGULATED BY MUSCLE ELECTRICAL ACTIVITY
Knockout mice lacking either Atrogin-1 or MuRF-1 exhibit reduced
denervation-induced muscle atrophy compared to Wt mice [Bodine
et al., 2001a]. Therefore, it is possible that Myog mediates its effects
on muscle atrophy by controlling Atrogin-1 and MuRF-1 gene
expression. Consistent with this idea, Atrogin-1 and MuRF-1
mRNAs, like Myog mRNA, are induced following muscle denerva-
tion (Fig. 4) [Bodine et al., 2001a] and Myog mRNA and protein
induction appears to precede Atrogin-1 and MuRF-1 mRNA
induction (Fig. 4). Denervation dependent gene regulation can
result from loss of trophic factors released from the motor neuron
[Mejat et al., 2003]; however, Myog gene expression is largely
Fig. 3. Myog deletion attenuates denervation-dependent reductions in muscle CSA. The left lower hindlimb muscles of Wt or Myog null (Myog/) mice were denervated for
14 days. Innervated and denervated EDL and soleus muscles were then dissected and muscle CSAs measured. (A) CSAs relative to the innervated control are reported.
Experiments were done in triplicate and three random areas from each muscle were sampled for fiber CSAs. Error bars are standard error of the mean. (B) Typical cross-section
through an innervated and denervated soleus muscle fromWt andMyog null (Myog/) mice. Note reduced denervation-dependent soleus muscle atrophy in Myog/mice. (C)
Adult hind limb muscles were denervated and 5 days later BrdU was injected (once daily) into animals for the next 8 days. Soleus muscles were collected and stained for laminin
(green) to identify the extracellular matrix, BrdU (red) to identify dividing cells and DAPI (blue) to visualize nuclei.
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regulated by muscle electrical activity independent of motor
innervation [Eftimie et al., 1991; Buonanno et al., 1992].
Interestingly, direct stimulation of denervated rat soleus muscle
with extracellular electrodes rapidly suppressed not only Myog, but
also Atrogin-1 and MuRF-1 gene expression (Fig. 5). Within 6 h
following stimulation of the denervated soleus muscle Myog,
Atrogin-1, and MuRF-1 mRNAs are dramatically reduced and by
24–48 h of electrical stimulation these mRNAs approach or are
below basal levels. These data suggest that all three of these mRNAs
are regulated by muscle electrical activity and are consistent with
the idea that Myog regulates Atrogin-1 and MuRF-1 gene
expression.
MYOG REGULATES ATROGIN-1 AND MURF-1 GENE EXPRESSION IN
DENERVATED MUSCLE
To directly test the idea that Myog controls atrophy-related gene
expression in denervated muscle, we compared Atrogin-1 and
MuRF-1 mRNA expression in Wt and Myog null mice. We also
assayed FoxO3 expression in these mice because FoxO3 contributes
to denervation-induced muscle atrophy [Sandri et al., 2004; Sandri
et al., 2006; Mammucari et al., 2007; Zhao et al., 2007], at least in
part, by stimulating Atrogin-1 gene expression [Sandri et al., 2004].
Therefore, Myogmay act onAtrogin-1 andMuRF-1 gene expression
directly or indirectly via regulated expression of FoxO3. To test these
possibilities we compared denervation-dependent gene expression
in Wt and Myog null mice. We chose 3 days post-denervation for
these assays because this is when Atrogin-1 RNA levels are reported
to be highest [Sacheck et al., 2007]. Real-time PCR showed that
muscle denervation induced Atrogin-1 mRNA by about 5.5-fold,
MuRF1 mRNA by almost 4-fold, andMyog mRNA by about 27-fold
(Fig. 6). Interestingly, these genes were not induced in Myog null
mice (Fig. 6). In contrast, FoxO3 mRNA expression does not appear
to be significantly regulated by muscle denervation (Fig. 6). These
data are consistent with the idea that Myog mediates denervation-
dependent induction of Atrogin-1 and MuRF-1 gene expression.
Because Atrogin-1 gene expression was more robustly regulated
bymuscle activity thanMuRF-1 gene expression, we focused on this
gene to further examine its regulation by Myog. To investigate if
Myog can induce Atrogin-1 gene expression in vivo, we
electroporated adult innervated soleus muscle with pCS2:Myog
and pCS2:EGFP expression vectors. Twelve days following
electroporation, soleus muscles were isolated, GFP-expressing fibers
dissected and RNA isolated for analysis of Myog, Atrogin-1, and g-
actin mRNA levels by real-time PCR. This analysis showed that
Myog over-expression induced Atrogin-1 mRNA levels (Fig. 7A).
These results suggest that Myog may directly activate the Atrogin-1
promoter. Indeed, inspection of the 3.5 kb Atrogin-1 promoter
identified eight putative Myog binding sites (E-boxes, CANNTG)
(Fig. 7). Interestingly, four of these sites conform to previously
identified Myog binding sites (CACCTG, CAGCTG) that have been
shown to be necessary for denervation-dependent activation of the
muscle-specific nAChR andMuSK promoters [Tang et al., 2006]. Co-
transfection of HEK 293 cells with an Atrogin-1:luciferase expres-
sion vector and pCS2-Myog showed Myog regulates Atrogin-1
promoter activity. In addition, a series of promoter deletions
indicated reduced promoter activity in both HEK 293 cells over-
expressing Myog (Fig. 7B) and in denervated soleus muscle (Fig. 7C)
that presumably reflects the reduction in Myog binding sites.
Deletion of distal E-boxes located between1 and3.5 kb from the
translation start site had a large consequence on the ability of Myog
to activate Atrogin-1 promoter activity in denervated muscle (Fig.
7C) and may suggest that these distal E-boxes play a more
significant role than the more proximal E-boxes in denervation-
dependent Atrogin-1 gene activation. Taken together, these data are
consistent with the idea that Myog mediates its effects on muscle
atrophy by directly regulating Atrogin-1 promoter activity.
DISCUSSION
The main finding from this study is that Myog expression
contributes to denervation-induced muscle atrophy. Myog is best
known for its role in muscle fiber formation during early
development where it is necessary for myoblast differentiation
and fusion [Hasty et al., 1993; Venuti et al., 1995; Vivian et al.,
Fig. 4. Denervation-dependent regulation of Myog, Atrogin-1 and MuRF-1
gene expression. Lower hindlimb muscles of adult mice were denervated for the
indicated times. Real-time PCR was used to quantify Myog, Atrogin-1, MuRF-
1, and Actin mRNA levels. RNA levels were normalized to Actin RNA levels and
then normalized to innervated RNA levels. Western blots were used to assay
denervation-dependent Myog protein induction. Myosin protein levels were
used to reveal differences in the amount of protein loaded onto the gel. Error
bars are standard error of the mean (n¼ 3).
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1999]. Postnatally, Myog expression is suppressed by muscle
innervation in an activity-dependent manner [Eftimie et al., 1991;
Buonanno et al., 1992]. Denervation of adult muscle induces Myog
expression where it plays an important role in mediating both
denervation-dependent gene induction and suppression [Tang et al.,
2004; Tang and Goldman, 2006; Tang et al., 2006; Tang et al., 2009].
Genes that are regulated, either directly or indirectly, by Myog
include those involved in synapse formation, muscle fiber
determination and muscle metabolism [Tang and Goldman, 2006;
Tang et al., 2009].
We were intrigued by the large induction in Atrogin-1 gene
expression following muscle denervation [Sacheck et al., 2007] and
tested the idea that denervation-dependent Myog expression
mediated this induction. Indeed our data suggests that Myog
regulates Atrogin-1 gene expression in denervated muscle which,
along with previously published data showing Atrogin-1 expression
contributes to muscle atrophy [Bodine et al., 2001a], is consistent
with the hypothesis that Myog contributes to denervation-induced
muscle atrophy.
We took advantage of mice that conditionally express Myog to
investigate its role in denervation-induced muscle atrophy. Previous
studies had shown that Myog is necessary for muscle fiber formation
during embryonic periods of development while loss of Myog
postnatally has little consequence on muscle growth [Hasty et al.,
1993; Venuti et al., 1995; Vivian et al., 1999; Knapp et al., 2006]. We
deletedMyog in adult mice and found that these mice exhibited less
denervation-induced muscle atrophy than Wt controls. This effect
was most pronounced for the slow soleus muscle and unremarkable
for the fast EDL muscle. This is not too surprising since previous
studies have documented that slow muscle fibers are more prone to
atrophy than fast muscle fibers [Grossman et al., 1998] and may
suggest that Myog and its targets, such as Atrogin-1, are
differentially regulated in fast and slow muscle fibers. Indeed basal
Fig. 6. Regulation of atrophy gene expression in Wt and Myog/ mice. The
left lower hind limb muscles of Wt or Myog null (Myog/) mice were
denervated for 3 days. Innervated and denervated soleus muscles were then
dissected and RNA extracted for RT-PCR (&). Ethidium bromide ( ) stained gel
shows the relative transcript levels. Real-time PCR was used to quantify these
levels which are shown in the graph. Note that Myog deletion blocks denerva-
tion-dependent induction of Atrogin-1, MuRF-1, and Myog mRNA expression
while FoxO3 mRNA expression is slightly increased in following muscle dener-
vation. Error bars are standard error of the mean (n¼ 3).
Fig. 5. Direct electrical stimulation of denervated soleus muscle suppresses denervation-dependent induction of Myog, Atrogin-1, and MuRF-1 mRNAs. Lower hind limbs of
adult rats were bilaterally denervated and stimulating electrodes were implanted into one hind limb. Denervated soleus muscles were electrically stimulated for 0–48 h. RNA was
isolated from innervated, 3-day denervated and 3-day denervated/stimulated soleus muscle and assayed by RT-PCR (representative ethidium bromide stained agarose gel is
shown) and real-time PCR (graph). Note that direct electrical stimulation of soleus muscle rapidly suppressed denervation-dependent Myog, Atrogin-1, and MuRF-1 gene
expression. Experiments were repeated twice with almost identical results.
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Myog expression is known to be higher in soleus compared to EDL
[Hughes et al., 1993; Voytik et al., 1993]. However, whether this
basal expression contributes to the differential atrophy noted in
soleus and EDL muscles is not clear.
We investigated if the protection against muscle atrophy is a
result of increased satellite cell proliferation and fusion with
existing muscle fibers in Myog knockout mice. Surprisingly, we
found that denervation-induced satellite cell proliferation is reduced
in Myog knockout mice and therefore, cannot account for the
maintenance of muscle mass or CSA in their denervated fibers. It has
been previously suggested that contact between muscle and nerve,
independent of muscle activity, is sufficient to suppress satellite cell
proliferation [Hyatt et al., 2003]. Our data suggests that Myog may
be a factor that mediates this effect of the nerve on muscle satellite
cells.
Of the genes previously shown to participate in muscle atrophy,
we identified Atrogin-1 as a putative Myog target. Data supporting
this idea include: (1) lack of Atrogin-1 induction following muscle
denervation in Myog knockout mice; (2) Myog over-expression in
innervated muscle induced Atrogin-1 gene expression; and (3)
Myog-dependent and denervation-dependent activation of the
Atrogin-1 promoter in tissue culture cells and soleus muscle,
respectively. Thus, Myog appears to mediate its effect on muscle
atrophy, at least in part, via activation ofAtrogin-1 gene expression.
MuRF-1mRNA was also induced in denervated soleus muscle ofWt
mice but not in Myog null mice which suggests Myog also
contributes to muscle atrophy by controlling denervation-depen-
dent induction of MuRF-1.
Previous studies have suggested thatAtrogin-1 andMuRF-1 gene
expression is regulated by the forkhead transcription factor, FoxO3
[Bodine et al., 2001b; Sandri et al., 2004]. FoxO3 activity is induced
by the PI3K/AKT signaling cascade and inhibited by PGC-1a
[Bodine et al., 2001b; Sandri et al., 2004; Sandri et al., 2006]. In
addition, NF-kB signaling also impinges on muscle atrophy, at least
in part, by increased expression of MuRF-1 [Cai et al., 2004;
Mourkioti et al., 2006]. There are no studies linking denervation-
dependent Myog gene expression to FoxO3 or NF-kB signaling
pathway, suggesting that denervation-dependent Myog gene
activation may be under the control of other signaling cascades.
The mechanism by which the Myog gene is activated in
denervated muscle is of interest because it may represent a new
target for reducing the detrimental consequences of muscle
denervation following injury or disease. We and others have
previously reported that denervation-dependent Myog gene induc-
Fig. 7. Myog regulates Atrogin-1 gene expression and Atrogin-1 promoter activity. (A) pCS2:Myog and pCS2:EGFP expression vectors were electroporated into innervated
soleus muscle of Wt animals. Twelve days later soleus muscles were harvested and GFP-expressing fibers dissected for RNA analysis. Real-time PCR was used to quantify Myog
and Atrogin-1 mRNA levels. Note Myog overexpression induced Atrogin-1 expression. Error bars are standard error of the mean (n¼ 3). (B) Atrogin-1 promoter activity is
regulated by Myog overexpression. HEK 293 cells were co-transfected with an Atrogin-1:luciferase reporter vector harboring various lengths of the Atrogin-1 promoter
upstream of the firefly luciferase sequence and a normalization vector ubC:Renilla luciferase that harbors the human Ubiquitin promoter upstream of the Renilla luciferase
sequence, with and without pCS2:Myog which allows for overexpression of Myog from the simian CMV promoter. (C) The soleus muscle of adult mice was electroporated with
Atrogin-1:luciferase reporter plasmid [Sandri et al., 2004], pCS2:EGFP to identify electroporated fibers and ubC:Renilla luciferase for normalization. 12 days post-
electroporation the left hindlimb muscle was denervated for 3 days and then GFPþ fibers were dissected from innervated and denervated electroporated muscles for luciferase
assays. Black ovals in the promoter cartoon indicate E-boxes (CANNTG) that conform to the consensus Myog binding E-box, while grey ovals represent E-boxes that do not
conform to this consensus sequence. Note the stimulation of Atrogin-1 promoter activity by Myog overexpression and muscle denervation and that as one deletes promoter
sequences harboring E-boxes, Myog-dependent and denervation-dependent Atrogin-1 promoter activation is reduced. Experiments were performed in triplicate. Error bars are
standard error of the mean (n¼ 3).
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tion is accompanied by translocation of HDAC4 to the nucleus and
that HDAC4 expression is necessary for Myog gene expression
[Cohen et al., 2007; Tang et al., 2009]. HDAC4 stimulatesMyog gene
expression by suppressing expression of the Myog gene transcrip-
tional co-repressors, Dach2 and MITR [Mejat et al., 2005; Tang and
Goldman, 2006; Cohen et al., 2007; Tang et al., 2009]. Myog also
stimulates HDAC4 gene expression, reinforcing the continued
expression of these genes in denervated muscle [Tang et al., 2009].
Interestingly, while this article was in preparation it was reported
that not only Myog, but also HDAC4 and 5 contribute to
denervation-induced muscle atrophy [Moresi et al., 2010]. This
latter study also came to the conclusion that Myog mediates its
effects on muscle atrophy by regulating Atrogin-1 andMuRF1 gene
expression. The HDAC4/5-Dach2-Myog signaling cascade impinges
on a large number of genes induced in denervated muscle that
influence muscle fiber metabolism, synapse formation, and atrophy
and therefore represents a potential target for reducing the
detrimental consequences of muscle atrophy following injury or
disease. However, because inhibition of this signaling pathway
would contribute to maintaining a pattern of gene expression more
like innervated muscle and because innervated muscle is resistant to
reinnervation, inhibition of this signaling pathway in denervated
muscle may preserve muscle mass at the expense of enhancing
muscle reinnervation.
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